4 big deal reports: Amgen-Horizon merger on the ropes
Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: potential block of |Horizon/Amgen transaction, merger deals at Magellan Midstream/Oneok and Urstadt...
Neutral
or
Horizon Therapeutics News & Analysis
-
-
Jefferies maintains Horizon Therapeutics at 'buy' with a price target of $116.50
An analyst from Jefferies maintained Horizon Therapeutics (NASDAQ: HZNP) at 'buy' with a price target of $116.50 from a prior price target of %currency%%price%. Prior to this rating,...
-
Midday movers: Home Depot, Capital One Financial, Tesla and more
Investing.com -- Stocks were mixed at midday Tuesday as investors waited for clarity on the direction of negotiations over raising the debt ceiling, with a June 1 deadline just weeks away....
-
U.S. stocks are falling after Home Depot report, weak retail sales
Investing.com -- U.S. stocks were falling on Tuesday after retailer Home Depot gave a weaker than expected forecast and April retail sales data showed consumers are feeling crunched. At...
-
Seagen sinks on concerns of heightened antitrust scrutiny of drug industry
Shares of biotech company Seagen (NASDAQ:SGEN) declined Tuesday morning, falling by over 6%. Weakness followed a report from Bloomberg overnight that suggested the Federal Trade Commission...
-
Horizon tumbles on potential FTC lawsuit to block Amgen deal; analysts surprised
Bloomberg News reported yesterday that the U.S. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed merger between Amgen (NASDAQ:AMGN) and Horizon...
-
Wells Fargo maintains Horizon Therapeutics at 'equal weight'
An analyst from Wells Fargo maintained Horizon Therapeutics (NASDAQ: HZNP) at 'equal weight' . Prior to this rating, Horizon Therapeutics had 1 buy ratings, 7 hold ratings, and 0 sell...
-
Horizon Therapeutics earnings missed by $0.37, revenue fell short of estimates
Investing.com - Horizon Therapeutics (NASDAQ: HZNP) reported first quarter EPS of $0.83, $0.37 worse than the analyst estimate of $1.20. Revenue for the quarter came in at $832.1M versus the...
-
Horizon Therapeutics to Present UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27 in...
-
Horizon Therapeutics Announces FDA Approval of Update to Indication Language for TEPEZZA to Specify its Use in TED Patients Regardless of Disease Activity or Duration
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage section of the TEPEZZA...
-
Horizon Therapeutics Reports Positive Topline Data from TEPEZZA Phase 4 Trial
-- 62% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis at Week 24 (≥ 2 mm) compared with 25% of patients receiving placebo --Horizon Therapeutics plc...
-
Horizon Therapeutics Announces New Analysis of MRI Findings Show UPLIZNA Reduced Formation of Asymptomatic Optic Nerve Lesions in People With NMOSD
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical...
-
Horizon Therapeutics Reports Real-World Experience Shows TEPEZZA Was Effective in Treating People With Dysthyroid Optic Neuropathy
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients with DON, the majority of...
-
Horizon Therapeutics Tops Q4 EPS by 12c
Horizon Therapeutics (NASDAQ:HZNP) reported Q4 EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942 million versus the consensus estimate of...
-
Horizon Therapeutics earnings beat by $0.12, revenue topped estimates
Investing.com - Horizon Therapeutics (NASDAQ: HZNP) reported first quarter EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942M versus the...
-
Horizon Therapeutics Reports New Data Suggesting UPLIZNA for Treatment of Neuromyelitis Optica Spectrum Disorder Did Not Increase Risk of COVID-19 Infection
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica...
-
Amgen Kicks Off 8-part Bond Sale To Fund Horizon Acquisition - Bloomberg
Amgen (NASDAQ:AMGN) Kicks Off 8-part Bond Sale To Fund Horizon Acquisition - Bloomberg
-
Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon
By Daniel Shvartsman Investing.com -- George Soros's fund Soros Fund Management opened new positions in Horizon Therapeutics (NASDAQ:HZNP) and First Horizon National Corporation (NYSE:FHN),...
-
5 biggest deals of 2022: Musk's Twitter buyout, Microsoft-Activision
As we head into 2023, here's a look back at a year that saw dealmaking slow into year-end amid rising interest rates by central banks, with three of the top five deals fraught with...
-
Midday movers: Horizon Therapeutics, Coupa Software, Microsoft and more
By Liz Moyer Investing.com -- Stocks are rising as investors await key inflation data and the Federal Reserve's decision on the next direction for interest rates. Here are the midday movers...
-
U.S. stocks rise as investors await inflation data and the Fed's rate decision
By Liz Moyer Investing.com -- Blue-chip stocks were rising but tech stocks wobbled as investors await inflation data and the Federal Reserve's next decision on interest rates later this...
-
Horizon Therapeutics, Microsoft, Gap rise premarket; Amgen, Rivian fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, December 12th. Please refresh for updates. Amgen (NASDAQ:AMGN) stock fell 3.2% after the Wall Street Journal...
-
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
-
Coupa stock soars on buyout news: 5 head-turning deal reports
Here are the 5 biggest deal dispatches from this past week, as covered first on InvestingPro+. Coupa Software (NASDAQ:COUP) was recently surging 26% in premarket trade Monday on news it had...
-
Dow futures rise 45 pts; rebounding ahead of Fed, CPI data
By Peter Nurse Investing.com -- U.S. stocks are seen opening marginally higher Monday, starting an important week that includes consumer inflation data and the final Federal Reserve...
-
Amgen to acquire Horizon for $26 billion as Sanofi drops bid - report
By Senad Karaahmetovic Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the...
-
Sanofi shares rise after French drugmaker ditches Horizon deal talks
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
-
European stocks weaken; caution ahead of central bank meetings
By Peter Nurse Investing.com - European stock markets retreated Monday, with investors cautious ahead of policy-setting meetings from the likes of the Federal Reserve and the European...
-
Rumors buzzing around Wall Street today
By Investing.com Staff Stocks were heavy Monday as positive economic data stirred concerns the Fed will have to maintain its hawkishness on rates. Amid the downside, several rumors swirled...
-
Horizon Therapeutics downticks as one of three bidders drops out
By Investing.com Staff Horizon Therapeutics (NASDAQ:HZNP) fell nearly 5% in early trading Monday after it was disclosed that one of the three original bidders for the company dropped...
-
7 biggest deal reports this week: Horizon Therapeutics surges on takeover talks
Here are 7 head-turning deal dispatches from the past week, as covered first on InvestingPro+. 1. Arco Platform (NASDAQ:ARCE) announced it had received a non-binding going private...
-
3 rumors lighting up trading screens today
By Investing.com Staff Stocks ripped higher after Fed Chairman Jay Powell said the Fed may slow rate hikes at the next meeting, pushing the Nasdaq up 4.4%, the S&P 500 up 3.1%, and the...
-
Midday movers: DoorDash, Workday, Hormel and more
By Liz Moyer Investing.com -- Stocks were struggling for direction on Wednesday as investors waited to hear what Federal Reserve Chair Jerome Powell will say in a speech he is scheduled to...
-
'Compelling value' in Viridian Therapeutics following Horizon Therapeutics acquisition talks
By Sam Boughedda Shares of Viridian Therapeutics (NASDAQ:VRDN) jumped Wednesday on the back of news on Tuesday evening that Horizon Therapeutics (NASDAQ:HZNP) is in "highly preliminary...
-
Horizon Therapeutics seen worth up to $140/share in takeover
By Investing.com Staff Several Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ:HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with ...
-
Workday, Boeing, Tesla and Airbnb rise premarket; Crowdstrike falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Wednesday, November 30th. Please refresh for updates. Crowdstrike (NASDAQ:CRWD) stock slumped 17% after the...
-
3 rumors pushing around stocks today
By Investing.com Staff Stocks edged lower Tuesday as traders watch developments in China around protests over the county's 'zero COVID' policy. Amid the downside action, several rumors...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
